TABLE 1.
Role of LINC00511 in breast cancer.
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Breast Cancer (BC) | Upregulated/Oncogene | 39 cases of breast cancer/MCF-10A, MDA-MB-468, MDA-MB-231, MDA-MB-453, MCF-7 | miR-185-3p/E2F1/Nanog axis | miR-185-3p/E2F1 | LINC00511/miR-185-3p/E2F1/Nanog axis has a role in breast cancer stemness and malignancy | Lu et al. (2018) |
| Upregulated/Oncogene | 10 TNTPs/MDA-MB-231, MCF-7 | LINC00511/miR-150/MMP13 axis | miR-150/MMP13 | The LINC00511/miR-150/MMP13 axis could represent a novel treatment strategy for sufferers with breast cancer, because it is a breast cancer promoter | Shi et al. (2021) | |
| Upregulated/Oncogene | MDA-MB-231, MCF-7, T47D, MDA-MB-468, MCF-10a | - | MET, E2F2, TGFA, and WNT10A | Patients with breast cancer who express LINC00511 more than usual have a bad outcome. Breast cancer progression is facilitated by LINC00511 | Liu et al. (2021a) | |
| Upregulated/Oncogene | 21 TNTPs/MDA-MB-231, MCF-7, Hs-578T, T47D, MCF-10A | LINC00511/miR-29c/CDK6 axis | miR-29c/CDK6 | Through controlling the miR-29c/CDK6 axis, LINC00511 lowering increased paclitaxel cytotoxicity in BC cells. A viable BC therapeutic option might be LINC005111 | Zhu et al. (2019) | |
| Upregulated/Oncogene | 25 patients and 25 control samples | LINC00511/miR-185-3p axis | miR-301a-3p | A more accurate diagnosis of BC may be made using serum LINC00511 and miR-301a-3p as prospective molecular indicators | Mahmoud et al. (2021) | |
| Upregulated/Oncogene | MDA-MB-231, MDA-MB-436 | LINC00511/miR-185/STXBP4 axis | miR-185/STXBP4 | Inhibition of LINC00511 reduces It has ability to bind competitively to miR-185, which boosts STXBP4 production and enhances radiation responsiveness in BC. A prospective treatment approach for boosting the prognosis of BC is the LINC00511/miR-185/STXBP4 axis | Liu et al. (2019) | |
| Upregulated/Oncogene | - | Apoptosis pathway | - | Through the suppression of antiapoptotic genes, LINC00511 deletion procedures using CRISPR/Cas9 improved the apoptosis of breast cancer cells | Azadbakht et al. (2022) | |
| Upregulated/Oncogene | MCF7, UACC-812, MDA-MB-231 | - | EZH2 and CDKN1B | In ER-negative breast cancer, lncRNAs have a role in controlling the network of cell cycle regulation, and this has led to speculation that LINC00511 may be used as an anticancer treatment | Zhang et al. (2019) | |
| Upregulated/Oncogene | 15 TNTPs | LINC00511/hsa-miR-573/GSDMC axis | miR-573/GSDMC | The most probable ncRNA-related mechanisms that drive GSDMC in BRCA are thought to be the LINC00511/hsa-miR-573 axis | Sun et al. (2022) | |
| Upregulated/Oncogene | 7 TNTPs (HER-2-enriched) | - | - | A putative chemical indicator and viable treatment option for breast cancer of the HER-2-enriched subgroup is LINC00511 | Yang et al. (2016) |